Use of GLP-1 receptor agonists in patients with T2DM and chronic kidney disease


    loading  Checking for direct PDF access through Ovid

Abstract

Diabetes mellitus is the leading cause of chronic kidney disease (CKD) in the US. An increasing number of glucagon-like peptide-1 receptor agonists are available for diabetes management. Differences between medications in this class, as well as limited data on patients with CKD, underscore the importance of a patient-centered approach to care.

    loading  Loading Related Articles